Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1653 1674
This examiner grants 71% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17800311 | SINGLE CHAIN TRIMER MHC CLASS II NUCLEIC ACIDS AND PROTEINS AND METHODS OF USE | Non-Final OA | California Institute of Technology |
| 19281547 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | Final Rejection | POVIVA CORP |
| 18271173 | ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18332150 | USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18247235 | PARTICLE BASED FORMULATION OF SARS-COV-2 RECEPTOR BINDING DOMAIN | Non-Final OA | The Research Foundation for The State University of New York |
| 17862825 | METHODS AND COMPOSITIONS RELATING TO HOT-START, ONE-STEP, REVERSE TRANSCRIPTION-COUPLED PCR | Non-Final OA | Wayne State University |
| 18019020 | STABLE PHARMACEUTICAL PREPARATION | Final Rejection | CELLTRION INC. |
| 18024819 | PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Final Rejection | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 17797644 | METHODS FOR THE TREATMENT OF HUNTER SYNDROME | Non-Final OA | DENALI THERAPEUTICS INC. |
| 18459394 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Non-Final OA | Janssen Sciences Ireland Unlimited Company |
| 18032902 | COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR METABOLIC SYNDROME, COMPRISING FLAGELLIN FUSION PROTEINS | Non-Final OA | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY |
| 18478711 | ANTIBODIES BINDING TO CD30 AND CD3 | Final Rejection | GENMAB A/S |
| 17801670 | FORMULATIONS OF ANTI-ENDOTHELIAL LIPASE ANTIBODIES | Final Rejection | MEDIMMUNE, LLC |
| 18344130 | METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | Final Rejection | Akron BioProducts LLC |
| 18033035 | CHIMERIC ANTIGEN COMPRISING THE EXTRACELLULAR DOMAIN OF PD-L1 | Non-Final OA | CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA |
| 18033484 | TRANSFORMED IMMUNE CELLS INDUCING CHEMOTAXIS TOWARDS HETEROGENEOUS IMMUNE CELLS | Non-Final OA | TSD LIFE SCIENCES CO., LTD. |
| 18028036 | TRANSDERMAL INSULIN FORMULATIONS AND METHODS OF USE THEREOF | Non-Final OA | Transdermal Delivery Solutions Corp. (d.b.a. HypoSpray Pharma) |
| 18026964 | COMPOSITION FOR TREATING OR PREVENTING DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH ENDOPLASMIC RETICULUM STRESS OR ALL-TRANS-RETINAL, PROTECTING RETINAL THICKNESS, OR SUPPRESSING REDUCTION IN RETINAL THICKNESS OR PROGRESS OF REDUCTION IN RETINAL THICKNESS | Non-Final OA | Restore Vision Inc. |
| 18245532 | MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Non-Final OA | Wagner ZAGO |
| 17624506 | METHOD FOR INDUCING NEURONAL SYNAPSE FORMATION AND MICROBEADS USED IN SAID METHOD | Non-Final OA | JIKSAK BIOENGINEERING INC. |
| 18024631 | DERIVATISATION OF PEPTIDES AND PROTEINS | Non-Final OA | FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH |
| 18016714 | INSULIN-FC FUSION PROTEIN AND APPLICATION THEREOF | Non-Final OA | JIANGSU GENSCIENCES INC. |
| 18004872 | FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF | Non-Final OA | GI INNOVATION, INC. |
| 17849626 | Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration | Final Rejection | America Great Health, a California Corporation |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy